Aprea Therapeutics Board Chair Christian Schade resigns; Richard Peters named Chair, Jean-Pierre Bizzari appointed

Aprea Therapeutics, Inc.

Christian S. Schade resigned as director and Board Chair on Aug 23, 2023; no disagreement with company.
Richard Peters, M.D., Ph.D. appointed Board Chair effective immediately after Schade's resignation.
Dr. Jean-Pierre Bizzari appointed as Class III director through 2025 annual meeting; previously at Celgene and Sanofi.
Annual meeting: Class I directors Duey, Peters, Seizinger elected (~1.55M for); auditor EisnerAmper LLP ratified (2.05M for).

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christian S. Schade

Chairperson of the Board and Director

APRE · Aprea Therapeutics, Inc.

Effective: 2023-08-23
Successor: Richard Peters
Filed: August 24, 2023, 7:59 PM ET

On August 23, 2023, Christian S. Schade resigned from the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”), including as Chairperson of the Board and any respective committee of the Board to which he was a member, effective immediately.

Appointed

Richard Peters

Chairperson of the Board

APRE · Aprea Therapeutics, Inc.

Effective: 2023-08-23
Filed: August 24, 2023, 7:59 PM ET

Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Richard Peters, M.D., Ph.D., to serve as Chairperson of the Board, effective immediately.

Appointed

Jean-Pierre Bizzari

Class III Director

APRE · Aprea Therapeutics, Inc.

Effective: 2023-08-23
Filed: August 24, 2023, 7:59 PM ET

Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Dr. Jean-Pierre Bizzari as a Class III director, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christian S. Schade resigned as Chairperson of the Board and Director at Aprea Therapeutics, Inc..

Action: resigned
Role: Chairperson of the Board and Director

Exact text from the filing

On August 23, 2023, Christian S. Schade resigned from the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”), including as Chairperson of the Board and any respective committee of the Board to which he was a member, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Peters was appointed as Chairperson of the Board at Aprea Therapeutics, Inc..

Action: appointed
Role: Chairperson of the Board

Exact text from the filing

Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Richard Peters, M.D., Ph.D., to serve as Chairperson of the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jean-Pierre Bizzari was appointed as Class III Director at Aprea Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Dr. Jean-Pierre Bizzari as a Class III director, effective immediately

View on SEC.gov

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-015237

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.